Objective: We evaluated our experience with segmental radiofrequency ablation (RFA) of the small saphenous vein (SSV), a less common procedure than great saphenous vein ablation, and developed a classification system and algorithm for endovenous heat-induced thrombus (EHIT), based on modifications of our prior algorithm of EHIT following great saphenous ablation. Methods: Endovenous ablation was performed on symptomatic patients with incompetent SSVs following a minimum of 3 months of compression therapy. Demographic data, risk factors, CEAP classification, procedure details, and follow-up data were recorded. A four-tier classification system and treatment algorithm was developed, based on EHIT proximity to the popliteal vein. Results: Eighty limbs (in 76 patients) were treated with RFA of the SSV between January 2008 and August 2012. Duplex ultrasound was performed between 24 and 72 hours postprocedure in all patients. Ablation was successful in 98.7% (79/80) of procedures. Sixty-eight (85%) patients had level A closures ($1 mm caudal to popliteal vein) and 10 patients (13%) had level B closures (flush with popliteal vein) and were observed. Two limbs (3%) had EHIT extending into the popliteal vein (level C) and were treated with outpatient low-molecular-weight heparin anticoagulation. Thrombus retracted to the level of the saphenopopliteal junction in both patients following a short course of anticoagulation. No patient developed an occlusive deep vein thrombosis (DVT) (level D). Mean follow-up period was 6.2 months; no patient had small saphenous recanalization, occlusive DVT, or pulmonary embolus. The presence or absence of the Giacomini vein was not predictive of level B and C closure. Conclusions: RFA of the SSV in symptomatic patients has a high success rate with a low risk of DVT. A classification system and treatment protocol based on the level of EHIT in relation to the saphenopopliteal junction is useful in managing patients. The approach to patients with thrombus flush with the popliteal vein or bulging has not been previously defined; our outcomes were excellent, using our treatment algorithm. (J Vasc Surg 2013;-:1-6.) 
Endovenous thermal ablation of the great saphenous vein (GSV) has become the preferred method of treatment for patients with symptomatic GSV reflux. In 2011, the Society for Vascular Surgery published Clinical Practice Guidelines recommending ablation rather than high ligation and inversion stripping for treatment of GSV incompetence to the knee. 1 Although the safety and efficacy of small saphenous vein (SSV) ablation has been validated by a small number of peer-reviewed studies, fewer published outcomes for this procedure exist in the current literature, in comparison to the GSV. [2] [3] [4] Furthermore, the great majority of these studies examine outcomes following laser ablation of the SSV alone with a paucity of published data available for patients treated with radiofrequency ablation (RFA). In this study, we report results following segmental thermal RFA of the SSV at our institution, using a classification system and treatment algorithm for management of the level of vein ablation.
METHODS
We reviewed our outcomes following 80 consecutive SSV ablations between 2008 and 2012. Preoperative risk factors, vein characteristics, anatomic variation at the saphenopopliteal junction (SPJ), postoperative level of ablation, treatment, outcomes, and complications were analyzed.
Patient selection. Patients with symptomatic SSV reflux evaluated at the UCLA Gonda Venous Center form the basis of this study. Six vascular surgeons performed the clinical evaluations; an independently interpreted duplex ultrasound was concomitantly performed in an accredited vascular lab. All duplex examinations were performed in the standing position under similar environmental conditions. Patients were recommended treatment based on symptoms and findings, compliance with medical therapy, and the identification of vein dilatation and reflux in the SSV in the symptomatic lower extremity while standing. The examining vascular surgeon assigned a CEAP classification to each patient and a value between 2 and 6 was required for endovenous therapy of the SSV. All patients underwent a trial of conservative, nonprocedural therapy for a minimum of 3 months, which included the following modalities: graded compression stockings (minimum of 20-30 mm Hg), leg elevation, and avoidance of prolonged standing. Patients with SSV reflux ($500 ms) who had continued symptoms after a trial of conservative therapy were considered candidates for RFA of the SSV. The largest diameter measurement of the SSV was used for this study. Anatomic variation of the Giacomini vein at the SPJ was categorized based on a previously published classification by Gibson et al 5 ; this classification is described in Table I .
Clinical setting for endovenous ablation. All procedures were performed in either an ambulatory surgery center or an office-based procedure center under local anesthesia and/or monitored anesthesia care, with location and anesthesia type based on patient preference, extent of venous disease, and insurance authorization. Concomitant or staged microphlebectomy was performed at the discretion of the surgeon for incompetent, symptomatic tributary veins measuring 3 mm or greater. Patients on chronic warfarin therapy were treated based on a previously published algorithm. 6 Based on this algorithm, patients on chronic warfarin were instructed to stop their oral anticoagulant 3 days prior to the procedure and instructed to restart the same night following RFA. The decision to bridge with low-molecular-weight heparin (LMWH) was made at the discretion of the patient's hematologist. Patients on aspirin and/or clopidogrel therapy were instructed to continue this treatment through the perioperative period.
Procedural techniques. All patients were treated using the manufacturer's instructions for use for the ClosureFast (VNUS Technologies, San Jose, Calif) RFA catheter (7F). All patients underwent SSV ablation with the ClosureFast catheter, which treats a 7-cm segment of saphenous vein to 120 C at 20-second intervals (segmental thermal ablation). The technique of stab phlebectomy was performed based on standard published techniques. 7, 8 Endovenous ablation of the SSV was performed in the prone position and ultrasound-guided puncture of the vein was performed at the distal ankle using a micropuncture needle. A 7F sheath was placed over a flexible guidewire, using Seldinger technique. Duplex ultrasound was used to position the tip of the catheter 2-3 cm caudal to the SPJ prior to treatment. In patients with no defined SPJ (n ¼ 4), the proximal extent of catheter placement was determined at the individual surgeon's discretion. Subcutaneous injection of tumescent anesthesia (saline, xylocaine, epinephrine, and sodium bicarbonate) was administered using a 23-g spinal needle to the tissues surrounding the SSV along its entire length prior to ablation. Following endovenous closure, patients were put in a compressive bandage with localized pressure along the treated SSV. This dressing is removed during the initial postoperative visit (24-72 hours) and continued use of compression stockings is recommended for 1-2 weeks.
Postclosure imaging and classification system. All patients underwent a postoperative duplex ultrasound 24 to 72 hours following SSV RFA to verify vein ablation and to assess the level of occlusion at the SPJ. We developed a classification system and treatment algorithm for endovenous closure levels at the SPJ ( Statistics. All data are presented as mean values. Statistical analysis included a two-tailed Fisher exact test for calculation of P values for categorical values (P < .05 was significant). A two-tailed Student t-test was used to calculate P values for all continuous variables. Multivariable analysis was performed using IBM SPSS 19.0 software (IBM, Armonk, NY) multiple linear regression.
RESULTS
Eighty consecutive segmental thermal ablations were performed in 76 patients between January 2008 and August 2012. The mean patient age was 65 6 17 years. Forty-seven patients were female (62%) and 29 (38%) were male. The mean preoperative vein diameter was 5.8 6 2.0 mm. Indications for endovenous ablation were lifestyle-limiting pain (n ¼ 80; 100%), edema (n ¼ 39; 49%), lipodermatosclerosis (n ¼ 5; 9%), and venous ulcer (n ¼ 32, 40%). Presenting signs based on CEAP classification are listed in Table II . Nine patients had a history of prior deep venous thrombosis (DVT), and all were on chronic warfarin therapy. In addition, two patients were on chronic warfarin for prosthetic heart valves. Ten patients (13%) were on chronic antiplatelet therapy (aspirin and/or clopidogrel) at the time of their procedures. No patient was on combined warfarin and antiplatelet therapy. Both patients with prosthetic heart valves were bridged with LMWH. LMWH was stopped 12 hours prior to the procedure and resumed the following morning. Prior vein procedures in our patient cohort are listed in Table III . Local anesthesia and oral valium was administered during 43 (54%) SSV ablation procedures. Local anesthesia alone was administered during 30 procedures (38%) and intravenous sedation (monitored anesthesia care) was administered in conjunction with local anesthesia during seven procedures (8%).
All patients (100%) underwent a postoperative duplex scan 24-72 hours following their procedure, and 98.7% (n ¼ 79/80) demonstrated duplex ultrasound evidence of closure of the treated SSV segment. One patient had continued patency of his SSV 2 days after ablation and declined further procedures. Twenty-nine patients (36%) underwent concomitant stab phlebectomy and eight (10%) underwent tributary vein removal in staged fashion for persistence of symptoms following SSV closure.
Based on our classification system for postoperative ablation at the SPJ, levels of closure were as follows: level A (n ¼ 68; 85%), level B (n ¼ 10; 13%), level C (n ¼ 2; 2%), and level D (n ¼ 0). All patients with level B ablation underwent a repeat duplex ultrasound in 1 week; no progression of thrombus into the popliteal vein occurred while on LMWH. Two patients developed level C endovenous heat-induced thrombus (EHIT) immediately following RFA and were treated with LMWH for a duration of 36 and 13 days, respectively. Neither of the two patients who developed level C closures were taking chronic warfarin prior to the ablation or had a history of prior DVT. Both patients were followed with weekly ultrasonography, and anticoagulation was terminated when there was ultrasound evidence of thrombus retraction into the SSV ($1 mm). In both patients with level C closure, retraction of thrombus to level A was noted following anticoagulation. No patient required long-term anticoagulation. The mean length of follow-up for the entire cohort was 6.2 months. No patient developed an occlusive deep venous thrombus, pulmonary embolus (PE), or required inpatient hospitalization.
Multivariate analysis was performed on various possible risk factors resulting in level B and C closures (Table IV) . A history of documented prior DVT and a vein diameter greater than 6 mm were both statistically significant risk 
DISCUSSION
No consensus guidelines exist for the treatment of EHIT following segmental ablation of either the GSV or SSV. Yet, despite the variability of treatment regimens for EHIT, the reported rates of occlusive DVT and PE following endovenous ablation of the GSV remain low. [9] [10] [11] [12] EHIT displays a distinct sonographic echogenicity compared with spontaneous acute DVT, and its natural history appears to be less prone to develop thrombus progression and extension. 13 Despite these differences, EHIT progression to PE has been reported in the literature and may result in life-threatening complications if not properly identified and treated. 14, 15 Because of differences in size and anatomic configuration between the GSV and SSVs, treatment protocols for ablation of the GSV are not readily transferrable without supporting data specific to SSV closure.
We developed and published a classification system and treatment algorithm for endovenous venous closure levels following GSV ablation to standardize treatment of EHIT at our institution. 16 Similar to our prior analysis of the GSV, segmental thermal ablation of the SSV resulted in immediate resolution of saphenopopliteal reflux with high vein closure rates in the majority of patients who underwent treatment across a wide range of CEAP classes. In fact, our patient population in this study trended toward more severe chronic venous insufficiency than similar published series. These results demonstrate that a novel classification system and treatment protocol for closure levels at the SPJ results in excellent outcomes following SSV ablation.
Despite its widespread use, there are only two small studies in the current literature reporting outcomes following RFA of the SSV. 3 Monahan et al treated 27 limbs over a 24-month period and demonstrated closure in all patients. Two developed EHIT extension into the popliteal vein (8%) and were treated with enoxaparin for 2 weeks with thrombus resolution. Bisang and colleagues performed RFA on 16 SSVs over a 2-year period and also demonstrated 100% occlusion. 17 One PE was noted in their series. There were no reported long-term nerve injuries in either study. Our results and complication rates compare favorably with these two studies.
Despite similar mechanisms of vein closure between radiofrequency and laser ablation, randomized trials comparing both modalities in the GSV have demonstrated significant differences in outcomes, including pain, analgesic requirements, and bruising. 18 Outcomes following laser ablation of the SSV are more numerous in the current literature with differing treatment protocols and algorithms. Gibson et al demonstrated an immediate technical success rate of 100% and EHIT extension into the popliteal vein in 12 patients (5.7%) 5 ; of these patients, nine were treated with a combination of enoxaparin and coumadin, two were treated with aspirin alone, and one was observed without medical therapy. No thrombus extensions or PEs were noted. Although EHIT occurred less frequently in our study, differences in rates of thrombotic complications between RFA and laser ablation of the SSV cannot be determined without randomized trials comparing both modalities.
The anatomic variability of the SSV and the SPJ has been well described. 19 However, the influence of anatomic factors on endovenous closure at this level has not been clearly delineated. In Gibson's study, the authors suggested that the presence of a Giacomini vein was protective against the development of thrombus protrusion into the deep venous system and that this vein served as a siphon to maintain patency of the SPJ, similar to the epigastric vein at the saphenofemoral junction. In contrast to Dr Gibson's series, we found no statistically significant relationship between level B and C closures in the presence or absence of a Giacomini vein. Similar to our prior study reporting our treatment algorithm following GSV ablation, an enlarged SSV diameter (>6 mm) and a history of prior DVT were the only significant risk factors for the development of closure flush with the popliteal vein or extension of EHIT into the deep venous system.
A potential limitation in our treatment algorithm is that asymptomatic patients (without residual or recurrent symptoms from their venous disease) did not undergo routine long-term follow-up ultrasound studies. Following the initial duplex scan 24-72 hours after RFA, only patients with evidence of EHIT or residual symptoms were rescanned. Our rationale behind this protocol is that endovenous therapy and/or phlebectomy is not indicated for asymptomatic patients who have a normal study postablation. Although the possibility exists that EHIT may develop after 24-72 hours, this has been extremely rare in our experience following ablation of the both the GSV and SSV. We also do not know whether outcomes would differ if EHIT JOURNAL OF VASCULAR SURGERY protrusion into the popliteal vein were not treated with anticoagulation. However, given the lack of thrombotic complications and PE in our series with this treatment algorithm, we continue to advocate the use of anticoagulation with level C and D closures until ultrasound evidence of thrombus retraction is confirmed. To our knowledge, this is the largest reported series of segmental thermal ablation of the SSV using the ClosureFast (VNUS Technologies) catheter. Our results demonstrate that RFA of the SSV can be performed with high safety and efficacy using the proposed classification system and treatment algorithm for levels of closure at the SPJ. Anatomic variation of the Giacomini vein and the SPJ did not influence levels of closure in this series, but vein diameter and prior DVT did; further large-scale, multiinstitutional analyses will be required to determine the significance of anatomic variations at the SPJ on levels of small saphenous ablation. ) . I would like to thank the authors for providing the manuscript well in advance of the meeting. The manuscript adds to existing literature supporting the success of heat ablation in duplex-documented closure of the SSV and the freedom from major complications such as nerve injury or clinically significant venous thrombosis. Literature regarding heat ablation of the SSV has been weighted more heavily toward laser ablation, and this paper shows that RFA appears to be safe as well. The objective of the paper was not to address or measure patient quality of life before or after treatment, but mainly to evaluate and discuss their algorithm for dealing with EHIT.
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Eighty limbs were included in the study and patient risk factors and anatomic variations of the SPJ were recorded preprocedure. Duplex-assessed vein closures were classified as levels A through D. Patients were examined 24-72 hours postprocedure. All but one had duplex-verified closure of the SSV, and only two out of 80 limbs had a level C occlusion. Both of these patients were treated with anticoagulation. There were no level D occlusions. Ten patients had level B occlusions, and all of these patients underwent follow-up duplex scans that showed no progression. Multivariate analysis of level B and level C occlusions showed only prior history of DVT and vein diameter greater than 6 mm increased risk of B or C occlusion. The anatomic variation scheme as proposed by my group in our 2007 JVS article had no impact on level of occlusion.
While I do believe that this paper adds to our existing data regarding the safety of heat ablation of the SSV, I have the following critiques:
(1) You included both level B and level C closures in your multivariate analysis of risk factors. You have shown that level B closures are benign in your paper, as you had no progression to an adverse event with observation.
We have seen that in our own practice as well; closures flush with SPJ do not progress. As such, I would argue that the level B closures are benign and should not be included in your multivariate analysis of risk factor for an adverse event. I suspect that not including them, and only leaving two adverse events in your series would make your data set too small to make meaningful observations about risk of thrombus extensions with heat ablation of the SSV. (2) I think the anatomic schema that was proposed by our group at this meeting in 2006 is too vague. Our series of 210 limbs had a much different breakdown of anatomic types; 43% had type A anatomy, compared with your 80%, 33% of our patients had a substantial Giacomini branch compared with 15% in your series, and 24% of our patients had no SPJ compared with 5% of your patients. I think the main problem with the schema proposed in our paper is the definition of what constitutes a major saphenopopliteal branch, which is not well defined by either paper. (3) You show that with your treatment algorithm of the two patients with thrombus extension, the patients did well and the thrombus resolved. What we do not know and what no paper that I know of has shown us is if these patients would have done well with no treatment whatsoever. Our main goal is the avoidance of life-threatening complications such as PE, and given there is no control group that is not treated, we do not know if your algorithm is protective. Questions:
(1) You noted in your manuscript that the diameter of the SSV was a significant risk factor for the development of an EHIT. Diameter of the SSV can vary greatly depending on patient positioning and location measured. Can you describe the technique used for scanning patients in your lab in terms of positioningeare the patients scanned while standing? What location of the SSV was used in your database? The largest diameter? The SPJ?
(2) You rescanned the patients with a "level B" closure to rule out progression of thrombus in the popliteal vein and found that in 10/10 patients, there was no progression. As a result of this study, are you no longer following these patients with serial scans? If not, why? (3) In your classification scheme, there were no patients with level D thrombus extension into the SSV and only two patients with any thrombus extension into the SSV (level C). Can you give us more information about these two patients? How far did the thrombus extend into the deep vein? Was it merely a bulge or adherent to the deep vein wall? As in most series describing the treatment of EHIT, there is no comparison, or nontreatment group. With your algorithm, all of the thrombus extensions resolved with treatment, and there appeared to be no complications from anticoagulation. Are there any "level C" thrombus extensions that you would believe comfortable observing rather than treating? Dr Juan Carlos Jimenez. Dr Gibson, thanks very much for your excellent questions. In response to the positioning of the patient during ultrasound examinations, all our patients are scanned in the standing position under similar environmental conditions. We used the largest diameter measured along the entire SSV in the lower leg. We did note that the largest diameter of the SSV in these patients was the SPJ.
Following the initial postoperative scan 24-72 hours following the small saphenous ablation, we obtain serial duplex scans for the following indications. One is to track the progression of EHIT for patients with closures flush to the SPJ or extension of thrombus into the popliteal vein. In our series, serial scans were performed until radiographic evidence of thrombus retraction into the SSV was demonstrated. Patients who returned at a later time with recurrence of symptoms are also rescanned. Our rationale for not retesting asymptomatic patients following great saphenous vein or SSV ablation is that these patients are not candidates for further invasive treatment regardless of vein patency. Only symptomatic patients demonstrating axial reflux are treated with ablation at our institution.
As for the two patients with thrombus extension into the popliteal vein, both had significant EHIT protrusion into the deep venous system and required 13 and 36 days of treatment with lovenox until the thrombus retracted. They were both at risk for further extension into the deep venous system if left untreated. Although serious thromboembolic complications are rare following these procedures, we have noted one pulmonary embolus following great saphenous ablation. Thus, at this point in our experience, we still believe therapeutic anticoagulation following EHIT extension into the deep venous system following radiofrequency saphenous ablation is the right thing to do.
